A once-weekly oral dose of isoniazid and rifapentine for 3 months (3HP) is recommended by
the CDC for treatment of latent tuberculosis infection (LTBI). The aim of this study is to …

Objectives: Using a nonhuman primate (NHP) model of TB, we sought to assess 3HP
treatment–mediated clearance of Mtb infection in latently infected macaques. Methods …

Rationale: Daily rifapentine plus isoniazid-pyrazinamide in mice infected with
Mycobacterium tuberculosis produces cure in 3 months. Whether cure corresponds to latent …

Rationale: Regimens recommended to treat latent tuberculosis infection (LTBI) are 3 to 9
months long. A 2-month rifampin+ pyrazinamide regimen is no longer recommended …

Rationale: Recent studies have demonstrated that combined substitutions of rifapentine for
rifampin and moxifloxacin for isoniazid in the standard, daily, short-course regimen of …

Rifapentine is a long-acting rifamycin which may be useful for intermittent drug therapy
against tuberculosis. In this study we measured the efficacies of rifapentine-containing …

Rationale: Multidrug-resistant and extensively drug-resistant tuberculosis (MDR/XDR-TB) is
an emerging global health threat. Proper management of close contacts of infectious …

The effectiveness of various once-weekly 10 mg/kg rifapentine (P)-containing regimens for
treatment of tuberculosis was assessed in mice infected intravenously with 4.3× 106 colony …

Rationale: Priorities for developing improved regimens for treatment of latent tuberculosis
(TB) infection include (1) developing shorter and/or more intermittently administered …

Targeting Mycobacterium tuberculosis bacilli in low-oxygen microenvironments, such as
caseous granulomas, has been hypothesized to have the potential to shorten therapy for …